Prospective study on warfarin and regional chemotherapy in patients with pancreatic carcinoma

Journal of Gastrointestinal and Liver Diseases

Volumn 17, Issue 3, 2008, Pages 285-290

  Nakchbandil, Wes ^a   Müller, Herwart ^a   Singer, Manfred V ^a   Löhr, J Matthias ^a   Nakchbandi, Inaam A ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Pancreatic carcinoma; Regional chemotherapy; Warfarin

Indexed keywords

CERTOPARIN; GEMCITABINE; MITOMYCIN C; WARFARIN;

ADULT; AGED; ANEMIA; ARTICLE; BILIRUBIN BLOOD LEVEL; BLEEDING; BLOOD TRANSFUSION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; LEUKOPENIA; LOW DRUG DOSE; MALE; MEDICAL RESEARCH; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; PANCREAS CARCINOMA; PANCREATICODUODENECTOMY; SIDE EFFECT; TREATMENT OUTCOME;

AGED; ANTICOAGULANTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; DEOXYCYTIDINE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; MITOMYCIN; PANCREATIC NEOPLASMS; PROSPECTIVE STUDIES; WARFARIN;

EID: 54349105928     PISSN: 18418724     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Goldberg R, Martenson J, Alberts S. Chemotherapy and radiaton therapy of pancreatic cancer. In: Rustgi A ed. Gastrointestinal cancers. Philadelphia: Elsevier Science Limited. 2003; 549-562.
2. Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first- line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15: 2403-2413.
3. Cello J. Pancreatic Cancer. In: Feldman M, Scharschmidt B, Sleisenger M eds. Sleisenger & Fordtran's Gastrointestinal and Liver Disease. 6th ed. Philadelphia: W.B. Saunders Company; 1998; 863-870.
4. Tsuchiya R, Tajima Y, Matsuzaki S, Onizuka S, Kanematsu T. Early pancreatic cancer. Pancreatology 2001; 1: 597-603.
5. Rosewicz S. Current aspects of diagnosis and therapy of pancreatic carcinoma. Z Gastroenterol 2002; 40 Suppl 2: 62-63.
6. Lohr JM. Medical treatment of pancreatic cancer. Expert Rev Anticancer Ther 2007; 7: 533-544.
7. Collins J. Pharmakologic rationale for regional drug delivery. J Clin Oncol 1984; 2: 498-504.
8. Ruo L, DeMatteo RP, Blumgart LH The role of adjuvant therapy after liver resection for colorectal cancer metastases. Clin Colorectal Cancer 2001; 1: 154-166.
9. Sadrian R, Niederbichler AD, Friedman J, et al. Intraarterial chemotherapy: the effects on free-tissue transfer. Plast Reconstr Surg 2002; 109: 1254-1258.
10. Chen HS, Gross JF. Intra-arterial infusion of anticancer drugs; theoretic aspects of drug delivery and review of responses. Cancer Treat Rep 1980; 64: 31-40
11. Ensminger WD. Intrahepatic arterial infusion of chemotherapy: pharmacologic principles. Semin Oncol 2002; 29: 119-125.
12. Schalhorn A, Peyerl G, Heinlein W, Wilmanns W. Dependence of systemic concentration on the infusion rate. Berlin: Springer. 1990.
13. Haas SL, Jesnowski R, Steiner M, et al. Expression of tissue factor in pancreatic adenocarcinoma is associated with activation of coagulation. World J Gastroenterol 2006; 12: 4843-4849.
14. Khorana AA, Ahrendt SA, Ryan CK, et al. Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer. Clin Cancer Res 2007; 13: 2870-2875.
15. Rudroff C, Seibold S, Kaufmann R, et al. Expression of the thrombin receptor PAR-1 correlates with tumour cell differentiation of pancreatic adenocarcinoma in vitro. Clin Exp Metastasis 2002; 19: 181-189.
16. Wojtukiewicz MZ, Rucinska M, Zacharski LR, et al. Localization of blood coagulation factors in situ in pancreatic carcinoma. Thromb Haemost 2001; 86: 1416-1420.
17. Wojtukiewicz MZ, Rucinska M, Zimnoch L, et al. Expression of prothrombin fragment 1+2 in cancer tissue as an indicator of local activation of blood coagulation. Thromb Res 2000; 97: 335-342.
18. Andren-Sandberg A, Lecandcr I, Martinsson G, Astedt B. Peaks in plasma plasminogen activator inhibitor-1 concentration may explain thrombotic events in cases of pancreatic carcinoma. Cancer 1992; 69: 2884-2887.
19. Wojtukiewicz M, Sierko E, Zimnoch L, Kozlowski L, Kisiel W. Immunohistochemical localization of tissue factor pathway inhibitor-2 in human tumor tissue. Thromb Haemost 2003; 90: 140-146.
20. Kakkar AK, Chinswangwatanakul V, Tebbutt S, Lemoine NR, Williamson RC. A characterization of the coagulant and fibrinolytic profile of human pancreatic carcinoma cells. Haemostasis 1998; 28: 1-6.
21. Nakchbandi W, Muller H, Singer MV, Löhr M, Nakchbandi IA. Effects of low-dose warfarin and regional chemotherapy on survival in patients with pancreatic carcinoma. Scand J Gastroenterol 2006; 41: 1095-1104.
22. Dawson-Saunders B, Trapp R. Basic and Clinical Biostatistics. Norwalk, CT, USA: Appleton & Lange. 1994.
23. Common toxicity criteria. ctepcancergov/forms/CTCv20_4-30-992pdf.
24. Schoenfeld D, Richter J. Nomograms for calculating the number of patients needed for a clinical trial with survival as an endpoint. Biometrics 1982; 38: 163-170.
25. Dupont W, Plummer WD Jr. Power and sample size calculations. A review and computer program. Controlled Clinl Trials 1990; 11: 116-128.
26. Berlin JD, Catalano P, Thomas JP, Kugler JW, Haller DG, Benson AB 3rd. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 2002; 20: 3270-3275.
27. Van Cutsem E, van de Velde H, Karasek P, et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 2004; 22: 1430-1438.
28. Lidestahl A, Permert J, Linder S, Bylund H, Edsborg N, Lind P. Efficacy of systemic therapy in advanced pancreatic carcinoma. Acta Oncol 2006; 45: 136-143.
29. Kohnoe S, Emi Y, Takahashi I, Yoshida M, Machara Y, Sugimachi K. Hypoxia and acidity increase the cytotoxicity of mitomycin C and carboquone to human tumor cells in vitro. Anticancer Res 1991; 11: 1401-1404.
30. Osieka R, Efferth T. Antineoplastische Substanzen. In: Schmoll HJ, Höffken K, Possinger K eds. Kompendium Internistiche Onkologie. Berlin Heidelberg: Springer Verlag Berlin Heidelberg New York. 1999.
31. Toschi L, Finocchiaro G, Bartolini S, Gioia V, Cappuzzo F. Role of gemcitabine in cancer therapy. Future Oncol 2005; 1: 7-17.
32. Icli F, Akbulut H, Utkan G, et al. Low molecular weight heparin (LMWH) increases the efficacy of cisplatinum plus gemcitabine combination in advanced pancreatic cancer. J Surg Oncol 2007; 95: 507-512.
33. Nakchbandi IA, Löhr JM. Coagulation, anticoagulation and pancreatic carcinoma. Nat Clin Pract Gastroenterol Hepatol 2008; in press.
34. von Delius S, Ayvaz M, Wagenpfeil S, Eckel F, Schmid RM, Lersch C. Effect of low-molecular-weight heparin on survival in patients with advanced pancreatic adenocarcinoma. Thromb Haemost 2007; 98: 434-439.
35. Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349: 146-153.
36. Lee AY, Rickles FR, Julian JA, et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol 2005; 23: 2123-2129.
37. Bobek V, Boubelik M, Fiserova A, et al. Anticoagulant drugs increase natural killer cell activity in lung cancer. Lung Cancer 2005; 47: 215-223.
38. Khorana AA, Sahni A, Altland OD, Francis CW. Heparin inhibition of endothelial cell proliferation and organization is dependent on molecular weight. Arterioscler Thromb Vasc Biol 2003; 23: 2110-2115.
39. Maraveyas A. Gemcitabine and dalteparin or gemcitabine alone for advanced pancreatic cancer (FRAGEM). http://www.cancerhelporguk/trials/ trials/
40. Oettle H, Riess H. A prospective randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy (PROSPECT). www.conko-studiende.